At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
MMBdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
In Brief
A Phase 2 clinical trial evaluating MMB for Primary Myelofibrosis (PMF) and 2 related conditions. Completed, enrolled 41 participants across 13 sites in 2 countries.
Detailed Summary
This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartJan 2016
Primary CompletionJul 2017
Study CompletionAug 2017
TodayJul 2026
First PostedAug 5, 2015
Enrollment StartJan 29, 2016
Primary CompletionJul 18, 2017
Study CompletionAug 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.9 years ago
Interventions
MMBdrug
Momelotinib (MMB) tablet administered orally once daily